Cadence Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Cadence Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-8,027	Closed	-$486K	–	694
2014 Q4	$486K	Buy	+8,027	New	+$403K	0.03%	503
2014 Q3	–	Sell	-8,800	Closed	-$544K	–	633
2014 Q2	$544K	Sell	8,800 -971	-10%	-$56.5K	0.03%	483
2014 Q1	$635K	Buy	+9,771	New	+$661K	0.03%	490

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadence Capital Management's OREX Position: Q1 2015 in Review

Cadence Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2015, closing a stake of 8,027 shares — an estimated $486K sold.

Cadence Capital Management first reported a position in OREX in Q1 2014 and held it in 3 quarters. The position peaked at $635K in Q1 2014. 160 funds tracked by Wall St. Rank hold OREX as of Q1 2015.

Cadence Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Cadence Capital Management sold 8,027 Orexigen Therapeutics, Inc. shares in Q1 2015, an estimated $486K.
Cadence Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
Cadence Capital Management's Orexigen Therapeutics, Inc. position peaked at $635K in Q1 2014.
160 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2015.

Based on Cadence Capital Management's 13F filing for Q1 2015, filed 30 Apr 2015.